paratek pharmaceuticals (nasdaq: prtk) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. we focus on drugs that target infectious disease and other difficult to treat conditions. our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against gram-positive, gram-negative and atypical bacteria. omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. the food and drug administration (fda) granted omadacycline a qualified infectious disease product (qidp) designation and completed two special protocol assessments for its phase 3 clinical trial program.
Company profile
Ticker
PRTK
Exchange
Website
CEO
Evan Loh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NOVACEA INC, Transcept Pharmaceuticals Inc
SEC CIK
Corporate docs
Subsidiaries
Paratek Ireland Limited • Paratek Pharma, LLC • Paratek Royalty Corporation • Paratek Securities Corporation • PRTK SPV1 LLC • PRTK SPV2 LLC • Transcept Pharma, Inc. ...
IRS number
330960223
PRTK stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
2 Oct 23
EFFECT
Notice of effectiveness
26 Sep 23
SC 13E3/A
Going private transaction (amended)
21 Sep 23
POS AM
Prospectus update (post-effective amendment)
21 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Sep 23
Transcripts
PRTK
Earnings call transcript
2023 Q1
9 May 23
PRTK
Earnings call transcript
2022 Q4
16 Mar 23
PRTK
Earnings call transcript
2022 Q3
4 Nov 22
PRTK
Earnings call transcript
2022 Q2
4 Aug 22
PRTK
Earnings call transcript
2022 Q1
5 May 22
PRTK
Earnings call transcript
2021 Q4
14 Mar 22
PRTK
Earnings call transcript
2021 Q3
9 Nov 21
PRTK
Earnings call transcript
2021 Q2
9 Aug 21
PRTK
Earnings call transcript
2021 Q1
17 May 21
PRTK
Earnings call transcript
2020 Q4
25 Feb 21
Latest ownership filings
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 42.81 mm | 42.81 mm | 42.81 mm | 42.81 mm | 42.81 mm | |
Cash burn (monthly) | (no burn) | 4.83 mm | 4.49 mm | 592.00 k | 1.93 mm | |
Cash used (since last report) | n/a | 47.87 mm | 44.49 mm | 5.86 mm | 19.16 mm | |
Cash remaining | n/a | -5.06 mm | -1.68 mm | 36.95 mm | 23.65 mm | |
Runway (months of cash) | n/a | -1.0 | -0.4 | 62.4 | 12.2 |
Institutional ownership, Q2 2023
14.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 15.26 mm |
Total shares | 8.17 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
NexPoint Real Estate Opportunities | 2.89 mm | $0.00 |
Hirschman Orin | 2.80 mm | $4.15 mm |
Dondero James D | 2.47 mm | $11.11 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
21 Sep 23 | Radie Robert S | Common Stock | Sale back to company | Dispose D | No | No | 0 | 20,000 | 0.00 | 0 |
21 Sep 23 | Radie Robert S | Common Stock | Sale back to company | Dispose D | No | No | 0 | 53,000 | 0.00 | 20,000 |
21 Sep 23 | Radie Robert S | Stock option Common Stock | Sale back to company | Dispose D | No | No | 24.07 | 20,000 | 481.40 k | 0 |
21 Sep 23 | Radie Robert S | Stock option Common Stock | Sale back to company | Dispose D | No | No | 14.05 | 12,000 | 168.60 k | 0 |
21 Sep 23 | Radie Robert S | Stock option Common Stock | Sale back to company | Dispose D | No | No | 15.1 | 6,000 | 90.60 k | 0 |
21 Sep 23 | Radie Robert S | Stock option Common Stock | Sale back to company | Dispose D | No | No | 14.15 | 5,000 | 70.75 k | 0 |
21 Sep 23 | Radie Robert S | Stock option Common Stock | Sale back to company | Dispose D | No | No | 7.23 | 5,000 | 36.15 k | 0 |
21 Sep 23 | Radie Robert S | Stock option Common Stock | Sale back to company | Dispose D | No | No | 3.51 | 7,000 | 24.57 k | 0 |
21 Sep 23 | Radie Robert S | Stock option Common Stock | Sale back to company | Dispose D | No | No | 7.61 | 7,000 | 53.27 k | 0 |
21 Sep 23 | Thomas John Dietz | Common Stock | Sale back to company | Dispose D | No | No | 0 | 20,000 | 0.00 | 0 |